A practical reference on REV-ERB agonist: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-01-27. Anything still debated is marked as such rather than presented as settled.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Visual inspection is not sufficient for identity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water. |
| Typical storage | -20 °C, desiccated, dark | Protect from repeated temperature changes. |
| Common analytical method | LC-MS or HPLC-UV | Reference standard required for comparison. |
| Common synonyms | SR9009; Stenabolic; REV-ERB agonist | Vendor naming may vary. |
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
For Mahathir, this was a significant enough slight to delay his entry into national politics in protest. He contested in the following general election in 1964, and was elected as the federal parliamentarian for the Alor Setar-based seat of Kota Setar Selatan. Elected to parliament in a volatile political period, Mahathir, as a backbencher, launched himself into the main conflict of the day: Singapore's future as a state of Malaysia. He vociferously attacked Singapore's dominant People's Action Party for being "pro-Chinese" and "anti-Malay" and called its leader, Lee Kuan Yew, "arrogant". Singapore was expelled from Malaysia in Mahathir's first full year in parliament. In 1965, Mahathir stated in Parliament that Article 153 of the Federal Constitution, which grants special rights to Malays, was a source of shame for the community and would eventually be abolished. Despite Mahathir's prominence, he lost his seat in the 1969 election, defeated by Yusof Rawa of the Pan-Malaysian Islamic Party (PAS). Mahathir attributed the loss of his seat to ethnic Chinese voters switching support from UMNO to PAS. Being a Malay-dominated seat, only the two major Malay parties fielded candidates, leaving Chinese voters to choose between the Malay-centric UMNO and the Islamist PAS. Large government losses in the election were followed by the race riots of 13 May 1969. Hundreds of people were killed in clashes between Malays and Chinese.
The perianth is undifferentiated (perigonium) and biseriate (two whorled), formed from six tepals arranged into two separate whorls of three parts (trimerous) each, although Scoliopus has only three petals, free from the other parts, but overlapping. The tepals are usually petaloid (petal like) and apotepalous (free) with lines (striate) or marks in other colors or shades. The perianth is either homochlamydeous (all tepals equal, e.g. Fritillaria) or dichlamydeous (two separate and different whorls, e.g. Calochortus) and may be united into a tube. Nectar is produced in perigonal nectaries at the base of the tepals. The androecium consists of six stamens in two trimerous whorls, with free filaments, usually epiphyllous (fused to tepals) and diplostemonous (outer whorl of stamens opposite outer tepals and the inner whorl opposite inner tepals), although Scoliopus has three stamens opposite the outer tepals. The attachment of the anthers to the filaments may be either peltate (to the surface) or pseudo-basifixed (surrounding the filament tip, but not adnate, that is not fused) and dehisce longitudinally and are extrorse (dehiscing away from center). The pollen is usually monosulcate (single groove), but may be inaperturate (lacking aperture: Clintonia, some Tulipa spp.) or operculate (lidded: Fritillaria, some Tulipa spp.), and reticulate (net patterned: Erythronium, Fritillaria, Gagea, Lilium, Tulipa).
Duchenne muscular dystrophy is caused by a mutation of the dystrophin gene, located on the short arm of the X chromosome (locus Xp21) that codes for dystrophin protein. Mutations can either be inherited or occur spontaneously during germline transmission, causing a large reduction or absence of dystrophin, a protein that provides structural integrity in muscle cells. Dystrophin is responsible for connecting the actin cytoskeleton of each muscle fiber to the underlying basal lamina (extracellular matrix), through a protein complex containing many subunits. The absence of dystrophin permits excess calcium to penetrate the sarcolemma (the muscle cell membrane).
== Structure, bonding, and characterization == Phenyl compounds are derived from benzene (C6H6), at least conceptually and often in terms of their production. In terms of its electronic properties, the phenyl group is related to a vinyl group. It is generally considered an inductively withdrawing group (-I), because of the higher electronegativity of sp2 carbon atoms, and a resonance donating group (+M), due to the ability of its π system to donate electron density when conjugation is possible. The phenyl group is hydrophobic. Phenyl groups tend to resist oxidation and reduction. Phenyl groups (like all aromatic compounds) have enhanced stability in comparison to equivalent bonding in aliphatic (non-aromatic) groups. This increased stability is due to the unique properties of aromatic molecular orbitals. The bond lengths between carbon atoms in a phenyl group are approximately 1.4 Å. In 1H-NMR spectroscopy, protons of a phenyl group typically have chemical shifts around 7.27 ppm. These chemical shifts are influenced by aromatic ring current and may change depending on substituents.
Sources: en.wikipedia.org
Food and Drug Administration (FDA) on 24 July 2015, and evolocumab (Repatha, Amgen), approved on 27 August 2015; both were also authorised in the European Union in 2015. Inclisiran (Leqvio, Novartis), a small interfering RNA (siRNA) that reduces PCSK9 production in the liver and is administered by twice-yearly injection, was subsequently approved by the European Medicines Agency in December 2020 and by the FDA in December 2021. PCSK9 inhibitors have been shown to significantly reduce LDL-C levels and increase HDL-C levels significantly. They were found to lower the incidence of myocardial infarction and stroke in individuals at high cardiovascular risk (over 15% using PREDICT cardiovascular disease calculator), such as those with at least five risk factors, established cardiovascular disease, or hereditary lipid disorders without cardiovascular risk factor, but not in those at low to moderate risk. A 2023 meta-analysis has indicated that alirocumab may reduce all-cause mortality, whereas evolocumab has no significant effect on all-cause mortality. The efficacy of bococizumab remains unclear, as its development was discontinued by Pfizer in 2016. The most recent guidelines for cholesterol management from the American Heart Association and American College of Cardiology now provide guidance for when PCSK9 inhibitors should be considered, particularly focusing on cases in which maximally tolerated statin and ezetimibe fail to achieve goal LDL reduction. A possible side effect of the monoclonal antibody might be irritation at the injection site.
İstivayı özler gözüm, (My eye seeks out repose,) Seb'al-mesânîdir yüzüm, (my face is the 'oft repeated seven (i.e. the Sura Al-Fatiha),) Ene'l-Hakk'ı söyler sözüm, (My words proclaim "I am the Truth",) Miracımız dardır bizim, (Our ascension is (by means of) the scaffold,) Haber aldık muhkemattan, (We have become aware through the "firm letters",) Geçmeyiz zâttan sıfattan, (We will not abandon essence or attributes,) Balım nihan söyler Hakk'tan, (Balım speaks arcanely of God) İrşâdımız sırdır bizim. (Our teaching is a mystery.) There is no official canon of Bektashism as the central tenet of Bektashism is "seeing the 72 nations in one eye" (which means all nations and religions are inherently same) and that "batin is more important than zahir", however there are generally accepted books attributed to the founding of the order. Makalat (The Articles), where the concept of four gates (sharia, tariqa, marifa, haqiqa) originate from, is according to Bektashis it was written by Haji Bektash Veli himself and by his order translated into local languages from Arabic in oral form and therefore in this form it is considered a central scripture. Another important book of Bektashism is Velayetname (The Book of Walayah), also attributed to Haji Bektash Veli himself, which gives a poetic account of the origin of the sect and the brief history of the faith as it spread through Anatolia. Other important writings are poetry of anonymous poet "Virani", the books of Kaygusuz Abdal, the Erkannames (Guiding Principles) and the poetry attributed to Shah Ismail.
Nutty Professor II: The Klumps is a 2000 American science fiction comedy film directed by Peter Segal and starring Eddie Murphy and Janet Jackson. It is the sequel to the 1996 film The Nutty Professor. In contrast to the previous film, subplots centered on the parents of protagonist Sherman Klump occupy a substantial part of the film. Nutty Professor II: The Klumps was released by Universal Pictures on July 28, 2000. Unlike its predecessor, the film received generally negative reviews and grossed $166.3 million.
Sources: en.wikipedia.org
Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.
The solid is usually kept desiccated at -20 °C or lower and protected from light. Stock solutions are aliquoted to limit freeze–thaw cycles. Aqueous solutions are not generally recommended for long-term storage.
Laws differ by country and by intended use. It is not an approved medicine, and many vendors sell it as a research chemical. Purchasers are responsible for confirming local restrictions.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.